Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 studyResearch in context

Summary: Background: Bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF) is currently available as a preservative-free, single-dose vial (SDV) presentation. RSVpreF offered in a multidose vial (MDV) may help reduce vaccination costs in lower-middle-income countries (LMI...

Descripció completa

Dades bibliogràfiques

Autors principals:	Uzma N. Sarwar, Jeffrey B. Baker, Lisa Pereira, Barbara A. Pahud, Jon Finley, David Strong, Sandra Pagnussat, Shyam Patel, Yanping Liu, Emma Shittu, Olympia Evdoxia Anastasiou, Elena V. Kalinina, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Iona Munjal
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-02-01
Col·lecció:	EClinicalMedicine
Matèries:	Immunogenicity LMIC Multidose vial RSV RSVpreF Safety
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589537026000143
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!